Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 3 1Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Leukemia, Myeloid, Acute 54Multiple Myeloma 45Lymphoma 44Lymphoma, Non-Hodgkin 41Leukemia 38Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Hodgkin Disease 35Myelodysplastic Syndromes 34Lymphoma, Mantle-Cell 20Lymphoma, Large B-Cell, Diffuse 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 19Leukemia, Lymphocytic, Chronic, B-Cell 16Burkitt Lymphoma 16Breast Neoplasms 13Neoplasms, Plasma Cell 11Recurrence 10Lymphoma, Follicular 10Hematologic Neoplasms 9Anemia, Refractory, with Excess of Blasts 9Lymphoma, B-Cell, Marginal Zone 8Neuroblastoma 7Myeloproliferative Disorders 7Lymphoma, Large-Cell, Immunoblastic 7Central Nervous System Neoplasms 7Blast Crisis 7Neoplasms 6Lymphoma, T-Cell 6Leukemia, Myelomonocytic, Juvenile 6Leukemia, Myelomonocytic, Chronic 6Graft vs Host Disease 6

Interventions

Oxaliplatin 67Capecitabine 60Fluorouracil 58Bevacizumab 54Gemcitabine 51Paclitaxel 50Leucovorin 50Irinotecan 40Docetaxel 39Carboplatin 39Cisplatin 38pembrolizumab 37Nivolumab 37Cetuximab 35Sunitinib 25Trastuzumab 24Radiosurgery 24Radiotherapy 21Doxorubicin 21Cyclophosphamide 21Panitumumab 20Drug Therapy 19Pemetrexed 18Everolimus 18Sorafenib 17Interleukin-2 16Fulvestrant 16Albumin-Bound Paclitaxel 16atezolizumab 15Erlotinib Hydrochloride 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neoplasm Metastasis × Granulocyte Colony-Stimulating Factor × Clear all
NCT03042780 2020-11-27

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
2 enrolled 6 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Islet Cell

NCT00393029 2011-08-15

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
12 enrolled 10 charts
Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡